Leukemia Archives

Residual Variants May Predict Relapse, Death in AML

March 28, 2023

The persistence of FLT3-ITD and/or NPM1 in blood is associated with relapse and worse survival among acute myeloid leukemia patients.

ONA Summit 2023

Achieving, Managing Patient Care During Maintenance Therapy for AML

By

Joyce Pagan

March 17, 2023

The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.

Leukemia

CAR-T Survival Outcomes Unrelated to Household Poverty and Neighborhood Opportunity in ALL

By

Vicki Moore, PhD

March 15, 2023

Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.

Leukemia

Texas-Mexico Border Residence Linked to Worse Survival in Children With ALL

By

Leah Lawrence

March 7, 2023

Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.

Leukemia

Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL

By

Laura Healy

March 6, 2023

Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.

Leukemia

AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”

By

Tori Rodriguez, MA, LPC, AHC

February 3, 2023

AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.

Leukemia

Charlson-Deyo Comorbidity Index Independent Predictor of Survival in Acute Promyelocytic Leukemia

By

Vicki Moore, PhD

January 30, 2023

Researchers sought to show an association between Charlson-Deyo Comorbidity Index and survival outcomes.

Leukemia

Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

By

Brian Park, PharmD

January 27, 2023

The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.